TNFRSF17 and Miyoshi myopathy: In another study of 38 patients with relapsed or refractory MM treated with a combination of CC-220 and DEX, these patients had previously received treatment targeting B-cell maturation antigen (BCMA), CD38 monoclonal antibodies, proteasome inhibitors, lenalidomide, or pomalidomide (NCT04975997).